The 2022 list of medical technologies approved for innovation funding (NUB) released in Germany

14

Feb 2022

On January 28, 2022, the Institute for the Hospital Remuneration System (InEK) has published the list of the requests for innovation funding (NUB) that were submitted by the hospitals in 2021.

Out of 868 submitted technologies, 251 (29%) received the positive status 1, which means that the suggested procedure or medical device met the NUB criteria, so now the hospitals can negotiate the innovation funding for these technologies with the sickness funds.

Furthermore, 32 (4%) technologies received differentiated status, which means that status 1 can be granted only under certain conditions.

The complete list of medical technologies (n=84, excluding pharmaceuticals), which obtained status 1, is provided below. The technologies are listed according to the number of received applications for funding. The technologies with differentiated status were not included in the list.

  1. Insertion of coated (covered) stents with the bioactive surface for peripheral vessels
  2. Covered endoprostheses with the bioactive surface for dialysis shunt revision
  3. Ascites treatment with a fully implantable pump
  4. External stabilization scaffold for anastomosis of an AV shunt as part of shunt surgery
  5. Endovascular placement of an internal AV shunt using magnetically guided high-frequency energy
  6. Intra-aortic catheter with paracorporeal membrane pump for circulatory support
  7. Flow-reducing wire mesh in the coronary sinus
  8. Hemodynamically effective implant for the endovascular treatment of intracranial aneurysms and cervical vessels supplying the brain
  9. Intraaneurysmal hemodynamically effective implant for the endovascular treatment of intracranial aneurysms
  10. Removable, ultra-soft microcoils for intracranial therapy of vascular malformations and aneurysms
  11. Transcatheter implantation of an interatrial shunt device for the treatment of heart failure
  12. Percutaneous transluminal insertion of an atrial septal implant for the treatment of heart failure
  13. Implantation of a gastric pacemaker
  14. Extracorporeal neurostimulation system for the peripheral nervous system
  15. Endovascular implantation of an extracorporeal centrifugal pump for circulatory support
  16. Focal photodynamic therapy with padeliporfin for the treatment of localized prostate cancer
  17. Administration of CAR-T cells for the treatment of hematological diseases
  18. Therapy of scoliosis using magnetically controlled rods
  19. Vertebral bodies growth modulation technique
  20. Transfer of virus-specific donor immune cells after allogeneic stem cell transplantation
  21. Endovascular mitral valve annuloplasty with annuloplasty band
  22. Transapical mitral valve reconstruction via implantation of neochordae (polytetrafluoroethylene, PTFE)
  23. Temporomandibular joint endoprosthesis (total replacement)
  24. Mesenchymal stem cells
  25. Minimally invasive left ventricle reconstruction with a myocardial anchoring system
  26. Percutaneous caval valve stent placement
  27. Intra-aortic balloon occlusion with extracorporeal circulation
  28. The wireless cardiac pacing system of the left ventricle for cardiac resynchronization therapy
  29. Insertion of coated (covered) stents with the bioactive surface for peripheral and other vessels
  30. Catheter-based implant for the treatment of left ventricular cardiac motility disorders
  31. Percutaneous transluminal implantation of an interatrial shunt for the treatment of heart failure with preserved or reduced left ventricular ejection fraction
  32. Therapy of scoliosis using a screw-rod system that grows with the patient
  33. Endovascular placement of a peripheral AV fistula by direct current
  34. Insertion of coated (covered) stents with a bioactive surface for intra-abdominal, cranial, or peripheral vessels
  35. Implantation of a heart valve that grows with the patient
  36. Endo-Exo prosthesis
  37. Endovascular implantation of a stent-graft with valve element in tricuspid valve insufficiency
  38. Replacement of the pulmonary trunk or parts of the aorta with an acellular allograft
  39. Thrombectomy of pulmonary vessels using the disc retriever system
  40. Performing a sleeve resection, endoscopically
  41. Radioligand therapy with Actinium-225-PSMA ligands
  42. Insertion of a colorectal bypass system to protect the anastomosis
  43. Radioimmunotherapy with anti-CD19, anti-CD45, and anti-CD66 antibodies
  44. Endoscopic intratumoral injection of phosphorus-32-labeled microparticles under ultrasound guidance in irresectable locally advanced pancreatic tumors
  45. Mesenchymal stem cells in therapy-resistant venous ulcers
  46. Apicoaortal, valve-bearing conduit
  47. Implant for direct acoustic stimulation of the cochlea (DACI)
  48. Insertion of coated (covered) stents with the bioactive surface for visceral and supra-aortic vessels
  49. Endoscopic thermal ablation of the duodenal mucosa to reduce insulin resistance
  50. Fetoscopic drainage therapy
  51. Continuous amniotic infusion using a subcutaneously implanted port system
  52. Acoustic neurinoma surgery with simultaneous cochlea implantation
  53. Endovascular mitral valve annuloplasty with anchorage of the suture
  54. Implantation of an intraocular lens with a magnification factor in macular degeneration
  55. Thyroplasty implant with the possibility of postoperative adjustment of vocal fold position
  56. Epiretinal retinal prosthesis
  57. Fetoscopic tracheal balloon closure in diaphragmatic hernia and premature rupture of the membranes
  58. Lutetium-177- or Yttrium-90 Pentixafor therapy
  59. Intracavitary radiotherapy with iodine-125
  60. Telemetrically adjustable pulmonary artery banding
  61. Closure of umbilical cord and intrafetal vessels using percutaneous ultrasound-guided radiofrequency ablation or fetoscopic laser ablation
  62. Boston keratoprosthesis
  63. Fetoscopic opening of narrowed semilunar valves and the foramen ovale
  64. Auditory brainstem implant
  65. Fetoscopic therapy of fetal supraventricular tachycardia and occlusion of the larynx or trachea
  66. Keratoprosthesis, biologically coated
  67. Uterine shield closure after fetoscopic surgery
  68. Growth endoprostheses
  69. Allogeneic hepatocyte transplantation
  70. Percutaneous transthoracic tricuspid valve replacement
  71. Radionuclide therapy with lutetium-177-bisphosphonate in bone metastases of prostate cancer
  72. Auditory middle brain implant
  73. Artificial larynx after total laryngectomy
  74. Radionuclide therapy with iodine-131-azetidinylamide in metastatic adrenal carcinoma
  75. Subretinal active implant
  76. Uterus transplantation
  77. Treatment of lethal epidermolysis bullosa junctionalis (M. Herlitz type) by transplanting haploidentical bone marrow and skin from the same donor
  78. Treatment of children with rhabdomyosarcomas of the bladder/prostate/rectum/perineal region with organ-preserving surgery and interstitial HDR brachytherapy
  79. Joint transplantations with thin-layered, fresh, living, allogeneic cartilage or bone material
  80. Gene therapy with autologous CD34+ enriched cells with ARSAGs for the treatment of metachromatic leukodystrophy
  81. Implantation of an intraocular lens in patients with macular diseases
  82. Combined renal and stem cell transplantation (living donation)
  83. Radionuclide therapy with iodine-131 metomidate
  84. Complete face transplantation

Seven new technologies (thrombectomy of pulmonary vessels using the disc retriever system, insertion of a colorectal bypass system to protect the anastomosis, endoscopic-intratumoral injection of phosphorus-32-labeled microparticles under ultrasound guidance in irresectable locally advanced pancreatic tumors, mesenchymal stem cells in therapy-resistant venous ulcers, endoscopic thermal ablation of the duodenal mucosa to reduce insulin resistance, implantation of an intraocular lens with a magnification factor in macular degeneration, implantation of an intraocular lens in patients with macular diseases) received status 1 in comparison with the 2021 list.

The full details in German can be found here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news).

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks). First EU issues of both newsletters are available for download free-of-charge.

The latest related news

30

Nov 2022

In November 2022, the National Board of Health and Welfare released the Swedish version of the NordDRG system to come into force in January 2023, including the list of DRG codes, names, and cost-weights. A total of 77 new DRGs will be implemented. Key new DRGs were introduced in cardiovascular, gastrointestinal, and endoscopy fields, also for breast reconstruction and bone-anchored hearing implants.

Read more

29

Nov 2022

On November 18, 2022, the Innovation Committee at the Federal Joint Committee (G-BA) announced that sixteen applications for Innovation Funding of the new forms of care were accepted. These applications relate to the funding announcement of March 17, 2021. Most projects relate to interdisciplinary or cross-sectoral care and pathways.

Read more

28

Nov 2022

The new version of the classification of procedure codes (CCAM v.71), applicable from December 03, 2022, was published in France. Several changes were introduced, including the creation of four new codes related to ENT, pulmonary and airways, and interventional radiology areas. Also, the modification of tariffs for 50 dental procedure codes will enter into force on January 01, 2023.

Read more

25

Nov 2022

In November 2022, Swedish Medical Technologies Product (MTP) Council issued a policy of proven experience for medical technology, which complies profession's assessment of how appropriate medical technology is in specific conditions. The policy provides some examples of how the MTP Council acquires knowledge of proven experience and its impact on the MTP Council's recommendations.

Read more

24

Nov 2022

In November 2022, NHS Digital published a final summary of core changes from OPCS-4.9 to OPCS-4.10 to be introduced from April 01, 2023. OPCS-4 is a statistical classification for clinical coding of interventions and procedures undertaken within the NHS. It is updated every three years. A total of 236 new four-character codes will be implemented in OPCS-4.10. Key changes concern cardiovascular, gastrointestinal, endoscopy, ENT, nephrology and urology, neurology and neurosurgery, obstetrics and gynecology, orthopedic, and breast surgery fields.

Read more